"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Lipoprotein(a), or Lp(a), was successfully reduced in phase II trials of muvalaplin and zerlasiran. (JAMA) The possibility of a drug interaction between SGLT2 inhibitors and statins was not supported ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

That is unlike low-density lipoprotein, also known as LDL or "bad cholesterol," which can be treated with lifestyle changes ...

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...

Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...